Staging Melanoma

Once cancer is diagnosed, a physician determines the stage of the cancer. Melanoma is categorized into one of five main stages (0 through IV). The size, location and whether the melanoma has spread are used to determine the stage.Table_1.jpgTable_2.jpg

Melanoma is usually staged twice. First, a physician will consider the results of the patient’s physical exam and any imaging tests that were done, and assign a clinical stage. Then, after a biopsy or surgical procedure, a pathologist will examine tissue taken from the tumor (and possibly nearby lymph nodes) and assign a pathologic stage. The second staging is more precise and is the key to deciding treatment options.

Both the clinical and pathologic stages of melanoma are classified according to the tumor, node, metastasis (TNM) system developed by the American Joint Committee on Cancer (AJCC) (see Table 2).

The first classification of the primary melanoma in the TNM system is for the thickness of the tumor (T). Each T classification is further divided into groups according to whether ulceration (a break in the outer layer of skin over the melanoma) is absent (subcategory a) or present (subcategory b). For example, a non-ulcerated melanoma 3 millimeters (mm) thick is classified as T3a, whereas an ulcerated melanoma 2 mm thick is classified as T2b. Another factor for thin melanomas (less than 1 mm thick) is the mitotic rate, which measures how fast the cancer cells are dividing and multiplying.

The node (N) classification is used to describe how many lymph nodes contain melanoma cells. The N category includes subcategories to describe the number of cancer cells in the lymph nodes. If the cancer cells in the nodes can be seen only with a microscope, the metastasis (spread) is considered to be microscopic (a). If enough cancer cells are in the lymph node that the doctor can feel the mass during a physical exam or can see the mass on an X-ray, it’s said to be “macroscopic” lymph node involvement (b). Another subcategory (c) indicates whether melanoma has spread to the lymphatic vessels leading to a lymph node. This is known as “in-transit melanoma,” which is metastatic melanoma found between the original tumor and the nearby cluster of lymph nodes.

The metastasis (M) category is used to classify the melanoma according to whether the cancer has spread beyond the region where the melanoma started to distant sites.

Once the melanoma is classified according to the TNM system, an overall stage of disease is assigned (see Table 1). Stage I and II melanomas are considered to be local (or localized) disease. Stage III melanoma is referred to as regional disease, and Stage IV is known as distant metastatic or advanced disease.

Stages_of_Melnoma.jpg

Open Forum Discussions

  • Hello! Attached are flyers for the Deep Dive Webinar Series and the Computational Immuno-oncology Webinar Series . Please share both with any colleagues that may be interested in ...

  • Hello, As fellow community members, I'm excited to share with you that SITC recently launched 2024 fellowships with $340,000 in available funding to advance cancer immunotherapy research. ...

  • Hello! There's less than two weeks left to save on Early Registration & Housing for the 2024 SITC Spring Scientific , Metabolism at the Hub of Cancer and Immunity. The Spring Scientific ...

  • The New York Academy of Sciences is proud to present Frontiers in Cancer Immunotherapy 2024 , which will take place in New York City on May 21-23, 2024. In its 11th year, the Frontiers ...

  • The Arthur and Sandra Irving Cancer Immunology Symposium Website: https://irvingcancerimmunologysymposium.com Hosted by Arthur and Sandra Irving, ...

SITC Resources

12-12-2022 10:54
This is the library for the Enduring Materials from the Targets for Cancer IO: A Deep Dive, TCR based therapies webinar that was conducted on December 7, 2022 . Date of Live Event: Wednesday, Dec. 7, 2022 – 2 p.m.–4 p.m. CST Moderators: Harlan Robins, PhD – Adaptive Biotechnologies ...
11-18-2022 17:51
Cancer Immunotherapy Winter School Sign up below to get an update when applications open for Winter School 2025 Tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings, this hybrid program provides ...
11-01-2022 13:02
On October 28, 2022, leading experts from the SITC Nonmelanoma Skin Cancer Immunotherapy Guideline Expert Panel presented "Case Studies in Immunotherapy for the Treatment of Nonmelanoma Skin Cancer – SITC CPG Webinar." This high-level webinar included case studies that illustrated execution of the Clinical ...
10-04-2022 12:12
On October 3, 2022, leading experts from the SITC Nonmelanoma Skin Cancer Immunotherapy Guideline Expert Panel presented "Practical Management Pearls for Immunotherapy for the Treatment of Nonmelanoma Skin Cancer — SITC CPG Webinar." This high-level webinar was designed to teach attendees how to appraise ...
10-04-2022 12:04
Nonmelanoma skin cancers (NMSCs) are some of the most commonly diagnosed malignancies. In general, early-stage NMSCs have favorable outcomes; however, a small subset of patients develop resistant, advanced, or metastatic disease, or aggressive subtypes that are more challenging to treat successfully. ...
09-28-2022 16:04
This is the library for the Enduring Materials from the Targets for Cancer IO: A Deep Dive, iPSC derived cell therapies webinar that was conducted on September 26, 2022 . Moderators: Kalle Malmberg, MD, PhD - Oslo University Hospital Jeffrey S. Miller, MD - University of Minne ...